Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy

Table 1 The clinical trials of drugs targeting LOX, Hsp47, integrins, YAP1 or TRPV4 (clinicaltrials.gov)

Trial ID	Target	Drug	Combination	Conditions	Phase	Estimated or actual enrollment	Status/results
NCT04676529	Pan-LOX	PXS-5505	None	Myelofibrosis	I/IIa	24	N.A
NCT02852551	LOXL2	PAT-1251	None	Healthy adults	I	78	This compound was well tolerated [140]
NCT04305496	LOXL2	PAT-1251	None	Myelofibrosis	II	21	Recruiting
NCT04183517	LOX	PXS-5382A	None	Healthy adults	I	18	N.A
NCT01369498	LOXL2	Simtuzumab	Ruxolitinib	Myelofibrosis	II	54	Simtuzumab alone or the addition of simtuzumab to ruxolitinib did not have clinical benefit [149]
NCT01472198	LOXL2	Simtuzumab	Gemcitabine	Pancreatic cancer	II	250	The addition of simtuzumab to gemcitabine did not improve clinical outcomes [146]
NCT01858935	Hsp47	ND-L02-s0201 injection	None	Healthy adults	I	56	Completed
NCT00689221	Integrin	Cilengitide	Temozolomide & radiotherapy	Glioblastoma	III	545	The addition of cilengitide to temozolomide chemoradiotherapy did not improve outcomes [161]
NCT04177108	Integrin	ATN-161	Carboplatin	Malignant glioma	I/II	82	Completed
NCT00066196	Integrin	MEDI-522	Dacarbazine	Metastatic melanoma	II	110	Completed
NCT00401570	α5β1Integrin	Volociximab	Gemcitabine	Metastatic pancreatic cancer	II	40	Completed
NCT04590664	YAP1	Verteporfin	None	Glioblastoma	I/II	24	Recruiting
NCT03033225	YAP1	Verteporfin	Photodynamic therapy	Advanced pancreatic carcinoma	II	30	Recruiting
NCT02119260	TRPV4	GSK2798745	None	Healthy subjects and heart failure patients	II	61	This compound is safe and well tolerated [153]

ISSN: 1756-8722